01-25-2019, 09:49 AM
(01-25-2019, 09:26 AM)stockguru Wrote: ABBV has become a real dud. Down $4 pre-market. One of those stocks that just can’t seem to get things right even with all dividend increases.
Just give it time. They are consistently profitable, have a fat yield, and grow the dividend regularly. I've noticed a lot of short-term price volatility with ABBV, usually related to analysts rehashing Humira/Humira biosimilar stories on a regular basis. Overall happy with the holding, considering initial purchase was in 2016 at $61.11
In the pharma space, I like to be pretty diversified. They all take turns seeing their pipelines dwindle, paying too much for acquisitions to fill the pipeline, and releasing drugs that kill or cripple people, all of which can make any given pharma company's stock pretty volatile in the short-run. Holding a basket of ABBV, AMGN, JNJ, LLY, MRK, PFE, SNY keeps me from caring too much when one of them gets volatile.